Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29379500 | 1.00 | HDAC1 (0.41) | HDAC1HDAC2HDAC4ALDH1A1HDAC6 | |
| SCHEMBL154742 | 1.00 | HDAC1 (0.41) | HDAC1HDAC2HDAC4ALDH1A1HDAC6 | |
| SCHEMBL3490800 | 0.99 | HDAC1 (0.40) | HDAC1HDAC2HDAC4ALDH1A1HDAC6 | |
| SCHEMBL29415489 | 0.99 | HDAC1 (0.40) | HDAC1HDAC2HDAC4ALDH1A1HDAC6 | |
| SCHEMBL107907 | 0.95 | ALDH1A1 (0.39) | HDAC1HDAC2HDAC4ALDH1A1HDAC6 | |
| SCHEMBL29356575 | 0.95 | ALDH1A1 (0.39) | HDAC1HDAC2HDAC4ALDH1A1HDAC6 | |
| SCHEMBL42368 | 0.91 | ALDH1A1 (0.44) | HDAC1HDAC2ALDH1A1MAPTKMT2A | |
| SCHEMBL29352062 | 0.91 | ALDH1A1 (0.44) | HDAC1HDAC2ALDH1A1MAPTKMT2A | |
| SCHEMBL29130297 | 0.89 | ALDH1A1 (0.48) | ALDH1A1MAPTKMT2ALMNA | |
| SCHEMBL43173 | 0.88 | HPGD (0.42) | HDAC1HDAC2HDAC4ALDH1A1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113039191-B | Nucleotide analogues | 奇异基因组学系统公司 | 2024-07-16 | — | — | CN | disclosed |
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | PFIZER INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | PFIZER INC. (US) | 2020-12-01 | — | — | US | disclosed |
| EP-3145934-B1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER (US) | 2020-11-11 | — | — | EP | disclosed |
| EP-3145934-B1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER (US) | 2020-11-11 | — | — | EP | disclosed |
| US-10813942-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | PFIZER INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10813942-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | PFIZER INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20190321382-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER INC. (US) | 2019-10-24 | — | — | US | disclosed |
| US-20190321382-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER INC. (US) | 2019-10-24 | — | — | US | disclosed |
| US-10376531-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | PFIZER INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-9340553-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | PFIZER INC. (US) | 2016-05-17 | — | — | US | disclosed |
| WO-2015177668-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| WO-2015177668-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| US-20150329555-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329555-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329555-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER INC. (US) | 2015-11-19 | — | — | US | disclosed |
| EP-0196007-B1 | DESMOSINE DERIVATIVES AND REAGENT FOR PREPARING ARTIFICIAL ANTIGENS | JAPAN TOBACCO INC. (JP) | 1990-01-10 | — | — | EP | disclosed |
| US-4841055-A | Desmosine derivatives and reagent for preparing artificial antigens | JAPAN TOBACCO INC. (JP) | 1989-06-20 | — | — | US | disclosed |
| US-4723012-A | Desmosine derivatives having a disulfide bond and preparation of artificial antigen using the same | JAPAN TOBACCO INC. (JP) | 1988-02-02 | — | — | US | disclosed |
| EP-0196007-A2 | Desmosine derivatives and reagent for preparing artificial antigens | JAPAN TOBACCO INC. (JP) | 1986-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329555-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | ASGR1, MRGPRX2, LDLR | HDAC1 3102/4885HDAC2 2626/4885HDAC4 3858/4885 |
| US-10813942-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | ASGR1, MRGPRX2, LDLR | HDAC1 3102/4885HDAC2 2626/4885HDAC4 3858/4885 |
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | ASGR1, LDLR, HAVCR2 | HDAC1 4131/4885HDAC2 2669/4885HDAC4 3083/4885 |
| US-20190321382-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | ASGR1, MRGPRX2, LDLR | HDAC1 3102/4885HDAC2 2626/4885HDAC4 3858/4885 |
| US-10376531-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | ASGR1, MRGPRX2, LDLR | HDAC1 3102/4885HDAC2 2626/4885HDAC4 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.